Back to Search
Start Over
Janssen Presents Findings from Global, Multi-Center Trial Examining Amivantamab in Combination with Lazertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
- Source :
- Legal Monitor Worldwide. September 22, 2020
- Publication Year :
- 2020
-
Abstract
- The Janssen Pharmaceutical Companies of Johnson & Johnson announced yesterday interim results from the CHRYSALIS study (NCT02609776) evaluating amivantamab, a fully human bispecific antibody that targets epidermal growth factor receptor [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Legal Monitor Worldwide
- Publication Type :
- News
- Accession number :
- edsgcl.636165686